This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015)
Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012)
Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21–45 (2016)
Author information
Authors and Affiliations
Contributions
N.M.A. produced and analysed the experimental data; T.B., Y.K., M.A.N., R.A.W. and B.Z.S. conceived and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
R.A.W. is listed as an inventor on three patent applications filed by the Whitehead Institute for Biomedical Research relating to the formation of cancer stem cells through activation of an EMT program. US patent application number US 14/441,697 describes a method to use PKC-α/FRA1 pathway inhibitors to target carcinoma cells that are identified by their increased expression of EMT-related genes. US patent application number US 15/307,657 describes a method to induce cancer stem cells to undergo EMT, rendering them amenable to conventional treatments. US patent application number US 14/065,311 describes methods for identifying compounds and compositions that target cancer stem cells, including cancer stem cells that have undergone EMT. R.A.W. is also listed as an inventor on two related patents that have been granted. US patent number US9212347 describes methods for preparing progenitor cells by inducing EMT. US patent number US9308238 describes methods and compounds for modulating and inducing EMT. R.A.W. is also a cofounder of Verastem Inc.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Aiello, N., Brabletz, T., Kang, Y. et al. Upholding a role for EMT in pancreatic cancer metastasis. Nature 547, E7–E8 (2017). https://doi.org/10.1038/nature22963
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature22963
This article is cited by
-
Research progress on the multi-omics and survival status of circulating tumor cells
Clinical and Experimental Medicine (2024)
-
Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy
Cancer and Metastasis Reviews (2024)
-
PEX26 Functions as a Metastasis Suppressor in Colorectal Cancer
Digestive Diseases and Sciences (2024)
-
N6-methyladenosine-modified MIB1 promotes stemness properties and peritoneal metastasis of gastric cancer cells by ubiquitinating DDX3X
Gastric Cancer (2024)
-
Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis
Genome Medicine (2024)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.